ARCH Venture Partners, a venture firm, led a $42m Series B round in Elephas, an imaging diagnostics, with participation from Moore Strategic Ventures, Tao Capital Partners, Northpond Ventures, Sands Capital, and WARF Ventures. "Technology that will allow patients to receive the most effective therapy quickly, before time and resources are spent on ineffective options, will change the game for those diagnosed with cancer. We are excited to partner with the company to bring this novel solution to patients," Paul Berns, ARCH Venture Partner.